Neuronetics Q4 Earnings Call Highlights
View original at finance.yahoo.comNeuronetics Q4 Earnings Call Highlights Neuronetics logo Key Points Board appointed Dan Reuvers as CEO effective March 23, as Neuronetics transitions leadership while continuing its strategy to operate a vertically integrated mental-health company combining NeuroStar technology and Greenbrook clinics…
Ce que nous avons tiré de cette source
The claims Via News extracted from this document. We point to the source; we don't replace it.
Operating cash burn improved sequentially each quarter during 2025, from negative $17 million in the first quarter to positive $0.9 million in the fourth quarter
60% confidenceNeuroStar revenue (systems plus treatment sessions) was $18.3 million for the quarter, representing 9% growth year-over-year on a pro forma basis
60% confidenceThe BMP program ended 2025 with more than 420 active sites and nearly 100 additional sites working toward qualification
60% confidenceCash provided by operations in the fourth quarter was positive $0.9 million
60% confidenceTotal cash was $34.1 million at Dec. 31, 2025, including $28.1 million of cash and cash equivalents and $6.0 million of restricted cash, compared with $19.5 million at year-end 2024
60% confidenceThe Greenbrook network is positioned to offer REMS-compliant therapies and expects only limited incremental investment to support COMP360 if approved, given alignment with existing Spravato operations
60% confidenceThe company's strategy following the Greenbrook acquisition was to build a vertically integrated mental health company combining technology, clinical infrastructure, and scale to expand patient access to treatment
60% confidenceNeuroStar revenue was $18.3 million for the quarter, representing 9% growth year-over-year on a pro forma basis
60% confidenceSince inception, the BMP program has connected more than 66,000 interested patients with BMP providers
60% confidenceTRICARE West expanded coverage for TMS therapy to include adolescents age 15 and older diagnosed with depression, effective across 26 states
60% confidenceThe Spravato rollout is nearly complete, with 84 clinics providing the treatment
60% confidenceHe expects a smooth transition to Reuvers, who he described as a medical-device leader with experience scaling commercial healthcare businesses
60% confidenceCOMP360 would be administered in supervised doses within a clinic setting, without a daily or recurring protocol, and would be administered under a REMS protocol similar to Spravato
60% confidenceThe combined company delivered strong fourth quarter results and reached a key milestone of positive operating cash flow in the period
60% confidenceFull-year clinic revenue grew 28% on an adjusted pro forma basis, supported by increased field engagement and a growing network of referring providers
60% confidenceFull-year clinic revenue grew 28% on an adjusted pro forma basis, supported by increased field engagement and a growing network of referring providers
60% confidenceThe clinic business is expected to grow in the double digits to mid-teens in 2026, while the NeuroStar business is expected to grow in the low to mid-single digits
60% confidenceCompass plans to submit an NDA with the potential for an FDA decision by year-end
60% confidenceGross margin was 52% in the fourth quarter, the company's highest quarterly margin of the year, citing clinic efficiency efforts and favorable product mix
60% confidenceThe clinic business is expected to grow in the double digits to mid-teens, while the NeuroStar business is expected to grow in the low to mid-single digits
60% confidenceThe company is focused on two initiatives in 2026: expanding how it brings NeuroStar TMS systems to market by piloting new customer acquisition models, and driving growth in demand at Greenbrook clinics for depression treatments
60% confidenceFull-year clinic revenue grew 28% on an adjusted pro forma basis, supported by increased field engagement and a growing network of referring providers
60% confidenceThe company's strategy following the Greenbrook acquisition was to build a vertically integrated mental health company combining technology, clinical infrastructure, and scale to expand patient access to treatment
60% confidenceCOMP360 would be administered in supervised doses within a clinic setting, without a daily or recurring protocol, and would be administered under a REMS protocol similar to Spravato
60% confidenceThe company shipped 49 systems in the quarter, with average selling price above its target for a fourth consecutive quarter
60% confidenceThe debt paydown would reduce annual interest expense by close to $600,000
60% confidenceClinic revenue was $23.5 million, representing 37% adjusted pro forma growth, driven by increased treatments across both NeuroStar TMS and Spravato
60% confidenceThe combined company delivered strong fourth quarter results and reached a key milestone of positive operating cash flow in the period
60% confidenceTRICARE West expanded coverage for TMS therapy to include adolescents age 15 and older diagnosed with depression, effective across 26 states
60% confidenceThe company shipped 49 systems in the quarter, with average selling price above its target for a fourth consecutive quarter
60% confidence